Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Eric Winquist

Showing results (111-120 of 234) with videos related to

Pageof 24
Sort By:
Urologic Oncology|October 22, 2022
UnCHAARTED territory: The role of docetaxel rechallenge following chemohormonal therapy for metastatic castration-sensitive prostate cancerMary Mahler, Esmail Al-Ezzi, Noa Shani Shrem, et al.
Investigational New Drugs|November 6, 2004
Phase I study of Tomudex and Doxorubicin in patients with locally advanced, inoperable or metastatic cancer (IND.98)Georg A Bjarnason, Danielle Charpentier, Ralph Wong, et al.
The Canadian Journal of Urology|May 10, 2005
Compliance and outcome of patients with stage 1 non-seminomatous germ cell tumors (NSGCT) managed with surveillance programs in seven Canadian centresD Scott Ernst, Penny Brasher, Peter M Venner, et al.
Current Oncology (Toronto, Ont.)|November 26, 2024
Clinical Outcome Patterns of Use of Radium-223 in Patients with Metastatic Castration-Resistant Prostate CancerColleen Mackenzie, Jasna Deluce, Morgan Black, et al.
Investigational New Drugs|July 26, 2011
A phase II study of sorafenib in combination with bicalutamide in patients with chemotherapy-naive castration resistant prostate cancerEmma K Beardsley, Sebastien J Hotte, Scott North, et al.
BMJ Supportive & Palliative Care|October 4, 2022
Duloxetine for prevention and treatment of chemotherapy-induced peripheral neuropathy (CIPN): systematic review and meta-analysisRonald Chow, Madison Novosel, Olivia W So, et al.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|September 25, 2012
An evaluation framework for funding drugs for rare diseasesEric Winquist, Chaim M Bell, Joe T R Clarke, et al.
The Oncologist|April 28, 2022
Lenvatinib for the Treatment of Radioiodine-Refractory Differentiated Thyroid Cancer: Treatment Optimization for Maximum Clinical BenefitLori J Wirth, Cosimo Durante, Duncan J Topliss, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 8, 2008
Nomograms to predict serious adverse events in phase II clinical trials of molecularly targeted agentsGregory R Pond, Lillian L Siu, Malcolm Moore, et al.
Pharmacoeconomics - Open|April 7, 2018
The Potential Clinical and Economic Value of Primary Tumour Identification in Metastatic Cancer of Unknown Primary Tumour: A Population-Based Retrospective Matched Cohort StudyMalek B Hannouf, Eric Winquist, Salaheddin M Mahmud, et al.
Pageof 24

Showing results (111-120 of 234) with videos related to

Sort By:
Pageof 24
Urologic Oncology|October 22, 2022
UnCHAARTED territory: The role of docetaxel rechallenge following chemohormonal therapy for metastatic castration-sensitive prostate cancerMary Mahler, Esmail Al-Ezzi, Noa Shani Shrem, et al.
Investigational New Drugs|November 6, 2004
Phase I study of Tomudex and Doxorubicin in patients with locally advanced, inoperable or metastatic cancer (IND.98)Georg A Bjarnason, Danielle Charpentier, Ralph Wong, et al.
The Canadian Journal of Urology|May 10, 2005
Compliance and outcome of patients with stage 1 non-seminomatous germ cell tumors (NSGCT) managed with surveillance programs in seven Canadian centresD Scott Ernst, Penny Brasher, Peter M Venner, et al.
Current Oncology (Toronto, Ont.)|November 26, 2024
Clinical Outcome Patterns of Use of Radium-223 in Patients with Metastatic Castration-Resistant Prostate CancerColleen Mackenzie, Jasna Deluce, Morgan Black, et al.
Investigational New Drugs|July 26, 2011
A phase II study of sorafenib in combination with bicalutamide in patients with chemotherapy-naive castration resistant prostate cancerEmma K Beardsley, Sebastien J Hotte, Scott North, et al.
BMJ Supportive & Palliative Care|October 4, 2022
Duloxetine for prevention and treatment of chemotherapy-induced peripheral neuropathy (CIPN): systematic review and meta-analysisRonald Chow, Madison Novosel, Olivia W So, et al.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|September 25, 2012
An evaluation framework for funding drugs for rare diseasesEric Winquist, Chaim M Bell, Joe T R Clarke, et al.
The Oncologist|April 28, 2022
Lenvatinib for the Treatment of Radioiodine-Refractory Differentiated Thyroid Cancer: Treatment Optimization for Maximum Clinical BenefitLori J Wirth, Cosimo Durante, Duncan J Topliss, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 8, 2008
Nomograms to predict serious adverse events in phase II clinical trials of molecularly targeted agentsGregory R Pond, Lillian L Siu, Malcolm Moore, et al.
Pharmacoeconomics - Open|April 7, 2018
The Potential Clinical and Economic Value of Primary Tumour Identification in Metastatic Cancer of Unknown Primary Tumour: A Population-Based Retrospective Matched Cohort StudyMalek B Hannouf, Eric Winquist, Salaheddin M Mahmud, et al.
Pageof 24